Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Bevacizumab + Pemetrexed + Cisplatin
Treatment for Mesothelioma
Typical Dosage: Bevacizumab 15mg/kg Q3W + Pemetrexed 500mg/m² Q3W + Cisplatin 75mg/m² Q3W
Effectiveness
65%
Safety Score
20%
Clinical Trials
3
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
20
DangerousModerateSafe
Treatment Details
Dosage Range
Bevacizumab 15mg/kg Q3W + Pemetrexed 500mg/m² Q3W + Cisplatin 75mg/m² Q3W
Time to Effect
6-9 weeks (initial response)
Treatment Duration
6 cycles + maintenance Bevacizumab
Evidence Quality
HIGHConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$80,000
Monitoring:$15,000
Side Effect Mgmt:$12,000
Total Annual:$107,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$175,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$194,545
Cost per Remission
$2,140,000
Comparison vs Pemetrexed + Cisplatin
Cost Difference
+$87,000/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Bevacizumab + Pemetrexed + Cisplatin Outcomes
for Mesothelioma
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+55%
Remission Rate
+5%
Common Side Effects
Neutropenia
+35%
Fatigue
+45%
Nausea/Vomiting
+30%
Hypertension
+25%
Proteinuria
+15%
Hemorrhage
+12%
GI perforation
+3%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for Bevacizumab + Pemetrexed + Cisplatin in Mesothelioma
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
NCT06543069RECRUITINGPHASE2
28 participants
INTERVENTIONAL
Beijing, China
Started: Jan 31, 2024
Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma
NCT07514793NOT YET RECRUITINGPHASE2
37 participants
INTERVENTIONAL
Shanghai, China
Started: Apr 1, 2026
Completed Clinical Trials
2 completed trials for Bevacizumab + Pemetrexed + Cisplatin in Mesothelioma
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
NCT00295503COMPLETEDPHASE2
53 participants
INTERVENTIONAL
Dallas, United States
Started: Feb 1, 2006
Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
NCT00651456COMPLETEDPHASE2, PHASE3
448 participants
INTERVENTIONAL
Aix-en-Provence, France +80 more
Started: Feb 1, 2008